TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~All subjects:~* Pathologically confirmed diagnosis of solid tumors~* Metastatic disease~* Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 1~* Adequate bone marrow, hepatic and renal function~* Normal Electrocardiogram (ECG)~* 18 years of age or above~* Able to understand and sign informed consent~Pilot study only:~- CRC, TNBC, ER/PR Breast Cancer, NSCLC, Pancreatic Cancer, Ovarian Cancer, Gastric Cancer, Gastroesophageal Junction (GEJ) adenocarcinoma, Head and Neck Cancer~Expansion Phase Additional Criteria:~* Locally advanced or metastatic breast cancer~* Received at least one cytotoxic therapy in the locally advanced and metastatic setting~* Received ≤ 5 prior lines of chemotherapy in the metastatic setting~* Candidate for chemotherapy~Expansion Phase Cohort 3 additional inclusion criteria:~* Breast cancer with active brain metastasis~* Neurologically stable~Exclusion Criteria:~* Active Central nervous system (CNS) metastasis (applies to pilot phase and expansion phase cohort 1 and 2 only)~* Clinically significant GI disorders~* Prior irinotecan or bevacizumab therapy within last 6 months and for Expansion Phase patients, have received any prior treatment with Topol inhibitor~* Known hypersensitivity to MM-398 or ferumoxytol~* Inability to undergo MRI~* Active infection~* Pregnant or breast feeding~* Prior chemotherapy administered within 3 weeks, or within a time interval less than at least 5 half-lives of the agent, whichever is longer, prior to the first scheduled day of dosing in this study~* Received radiation therapy in the last 14 days~* Treated with parenteral iron in the previous 4 weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pilot Phase: Ferumoxytol followed by MM-398 (Type: EXPERIMENTAL): Ferumoxytol 5 mg/kg IV at the rate of 1 mL/sec, given once on Day 1. MM-398 IV over 90 min on Days 1 and 15 of every 4 week cycle
- Expansion Phase: Ferumoxytol followed by MM-398 (Type: EXPERIMENTAL): Ferumoxytol 5 mg/kg IV at the rate of 1 mL/sec, given once on Day 1. MM-398 IV over 90 min dose 1 on Days 1 and 15 of every 4 week cycle Cohort 1: ER and/or PR-positive BC Cohort 2: TNBC Cohort 3: BC with active brain metastasis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and Pharmacokinetics of NTP42:KVA4

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A body mass index (BMI) in the range 18.0-30.0.~* Ability \& willingness to provide written consent.~Exclusion Criteria:~* Clinically relevant abnormal medical history, physical findings, laboratory values at pre-trial screening.~* History of bleeding disorders, coagulation variables or abnormal blood cell count.~* History of chronic illness.~* Impaired endocrine, thyroid, hepatic, renal or respiratory function, diabetes mellitus, coronary heart disease or history of any psychotic mental illness.~* History of adverse reaction or allergy to any drug.~* Use of aspirin, other non-steroidal anti-inflammatory drugs (NSAIDs), or any other medicine that affects platelet function or coagulation, or any prescription medicine, during the 28 days before the first dose of trial medication.~* History of drug or alcohol abuse~* Smoker or use of nicotine-containing products~* Blood pressure or heart rate at screening outside normal ranges.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- NTP42:KVA4 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Egg Allergy in Children Through Oral Desensitization (EGG OIT)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Between 1 to 16 years of age~* Diagnosed egg allergy by CAP FEIA to egg of 5 kU/l or greater (2 kU/l or greater if 2 years old or less) or have had a positive allergic reaction to egg within 6 months.~* Having eaten egg in his/her diet prior to diagnosis~* A family that will be able to be compliant with all study visits~* All females of child bearing age must be using appropriate birth control~Exclusion Criteria:~* History of anaphylaxis to egg~* Medical history that would prevent a DBPCFC (double-blind placebo-controlled food challenge) to egg. The medical history that would prevent the DBPCFC to egg would be a prior history of an open egg challenge in which the patient experienced hypotension which required fluid resuscitation, respiratory compromise which necessitated ventilatory support, or poorly controlled asthma as evidenced by an FEV1 \< 80% of predicted, or FEV1/FVC \<75%, with or without controller medications~* Unable to cooperate with challenge procedures or unable to be reached by telephone for follow-up~* Diagnosed corn allergy

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Egg white protein (Type: EXPERIMENTAL): Subjects, who are egg allergic, are given egg white protein for desensitization with the hypothesis they will develop tolerance.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have undergone a human leukocyte antigen (HLA) matched (sibling) allogeneic HCT for a hematologic or lymphoid malignancy other than chronic myelogenous leukemia (CML) who have recurrent or persistent disease and are otherwise eligible for donor leukocyte infusions CML patients with persistent disease after receiving donor lymphocyte infusion of at least 1x10\^8cells/kg will be eligible for CD8+ memory T cell infusion~* Patients must have no evidence of active graft-versus-host disease and must be on a stable immunosuppressive regimen without a change in drugs dosage in the 4 weeks prior to the planned CD8+ memory T cell infusion~* Patients must not have any active infections~* Patients must have a performance status of \> 70% on the Karnofsky scale~* Serum creatinine of \< 2 mg/dl or creatinine clearance of \> 50 cc/min~* Bilirubin of \< 3 mg/dl Transaminases \< 3 times the upper limit of normal~* Patients must have negative antibody serology for the human immunodeficiency virus (HIV1 and 2) and hepatitis C virus and negative test for hepatitis B surface antigen~DONOR:~* Donors must be an HLA matched sibling~* Donors must be 18-75 years of age, inclusive~* Donors must be in a state of general good health~* Donors must have a white blood cell count \> 3.5 x 10\^9/liter DONOR: Platelets \> 150 x 10\^9/liter~* Donors: Hematocrit \> 35%~* Donors must be capable of undergoing leukapheresis~* Donors must not be seropositive for HIV 1 and 2, Hepatitis B surface antigen, Hepatitis B core antibody, Hepatitis C antibody, human T-lymphotropic virus (HTLV) antibody, cytomegalovirus (CMV) immunoglobulin (Ig)M, or Rapid Plasma Reagin (RPR) (Treponema)~* Female donors must not be pregnant or lactating~Exclusion Criteria:~* Diagnosis of CML except patients who have failed prior donor leukocyte infusion with a minimum cell dose of 1x10\^8 cells/kg~* Patients who have been diagnosed with a second cancer (except carcinoma in situ of the cervix and basal cell carcinoma of the skin) which is currently active or has been treated within three years prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (DLI) (Type: EXPERIMENTAL): Patients undergo CD8+ memory T-cell infusion over 10-20 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Esomeprazole in PPI Failures - IMPROVE

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Provision of informed consent~* Male or female, aged 18-65 years~* History of GERD symptoms during, at least, six months prior to enrolment~* PPI as maintenance treatment during the last 30 days prior to enrolment~* Heartburn as predominant GERD symptom, as judged by the investigator~* Persisting GERD symptoms during the past 7 days prior to visit 1, judged by the patient as either: 4 days with mild symptoms (i.e. awareness of sign or symptom, but easily tolerated)or 2 days with moderate (i.e. discomfort sufficient to cause interference with normal activities) to severe symptoms (i.e. incapacitating, with inability to perform normal activities)~Exclusion Criteria:~* Any treatment with esomeprazole during 30 days prior to enrolment History of esophageal, gastric or duodenal surgery, except for simple closure of an ulcer~* Current or historical evidence of the following diseases/conditions, as judged by the investigator:Zollinger-Ellison syndrome,Primary esophageal motility disorder, i.e. achalasia, scleroderma, primary esophageal spasm,~* Gastric or duodenal ulcers within the last three months, Malabsorbtion~* Malignancy or other concomitant disease with poor prognosis or which may interfere with the assessments in the study~* Unstable diabetes mellitus. Stable diabetes controlled by diet, oral agents or insulin is acceptable~* Patients with severe diseases or disorders which may interfere with the conduct of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Puerto Rico Cuidalos Parent-adolescent Program

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* one parent and one son or daughter between 13 and 17 years of age must agree to be in the study~* in Puerto Rico~Exclusion Criteria:

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Parental communication intervention (Type: EXPERIMENTAL): The parental experimental intervention consists of a 60-minute web-based intervention consisting of several modules.
- Health promotion control condition. (Type: ACTIVE_COMPARATOR): The Health promotion control condition will be web-based and provide useful information for Puerto Rican parents and youth.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of the Pediatric Formulation of Artemether- Lumefantrine in Children With Uncomplicated P. Falciparum Malaria.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* male or female infants and children ≤12 years of age~* body weight of ≥5 kg and \<35 kg,~* with a confirmed diagnosis of uncomplicated malaria caused by the P. falciparum parasite~Exclusion Criteria:~* complicated malaria~* persistent vomiting~* malaria due to parasites other than P. falciparum~* antimalarial treatment received in the past 2 weeks~* known chronic disease e.g. positive HIV status, severe cardiac, renal, or hepatic disease

- Gender: ALL
- Minimum Age: None
- Maximum Age: 12 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pre-clinical Cardiac Dysfunction Among Asymptomatic Hypertensive Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Blood pressure \> or = 140/90 after 1 hour~* Asymptomatic state as defined by Goldman Specific Activity Scale~Exclusion Criteria:~* Dyspnea (exertional or nocturnal) or chest pain as a primary or secondary chief complaint~* Prior history of heart failure, coronary artery disease, myocardial infarction, cardiomyopathy, valvular heart disease or renal failure (with current, previous, or planned future dialysis)~* Patients with acute illness or injury which necessitates hospital admission~* Standing relationship with usual source of health care (i.e., primary care provider)

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- BP < 140/90 mmHg (Type: ACTIVE_COMPARATOR): This arm will target a blood pressure of \< 140/90 mmHg (or \< 130/90 mmHg for diabetics or those with chronic kidney disease) as indicated by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure.
- BP < 120/80 mmHg (Type: EXPERIMENTAL): This arm will target a more aggressive blood pressure target of \< 120/80 mmHg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Insulin Glargine All to Target Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
* Male or female patients~* 30 to 80 years of age~* Body Mass Index \<45 kg/m2~* With Type 2 diabetes mellitus for at least 2 years~* With an HbA1c level at screening of \>7.5% and \>7.0% at randomization~* On stable dual or triple oral therapy for at least 3 months~* Oral agents in 2 or 3 of the following classes: SU or repaglinide, biguanide, or TZD, willing and able to perform self-monitoring of BG~* Females of child-bearing potentially were required to be willing and able to use adequate contraception

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Lantus/Apidra-3 (Type: EXPERIMENTAL): Insulin glargine (Lantus) plus up to 3 injections of insulin glulisine (Apidra) added to oral agents.
- Lantus/Apidra-1 (Type: EXPERIMENTAL): Insulin glargine (Lantus) plus up to 1 injection of insulin glulisine (Apidra) added to oral agents.
- Novolog Mix 70/30 (Type: EXPERIMENTAL): Premixed insulin (Novolog® Mix 70/30) added to oral agents.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Men and women 18 to 60 years of age at screening.~* Clinical diagnosis of FOP (based on findings of congenital malformation of the great toes, episodic soft tissue swelling, and/or progressive heterotopic ossification (HO)).~* Confirmation of FOP diagnosis with documentation of any ACVR1 mutation.~* FOP disease activity within 1 year of screening visit. FOP disease activity is defined as pain, swelling, stiffness, and other signs and symptoms associated with FOP flare-ups; or worsening of joint function, or radiographic progression of heterotopic ossifications (increase in site or number of HO lesions) with/without being associated with flare-up episodes.~* Willing and able to undergo PET and CT imaging procedures and other procedures as defined in this study.~Key Exclusion Criteria:~* Significant concomitant illness or history of significant illness such as, but not limited to cardiac, renal, rheumatologic, neurologic, psychiatric, endocrine, metabolic or lymphatic disease, that in the opinion of the study investigator might confound the results of the study or pose additional risk to the patient by their participation in the study.~* Previous history or diagnosis of cancer.~* Use of bisphosphonate within 1 year of screening.~* Concurrent participation in another interventional clinical study, or a non-interventional study with radiographic measures or invasive procedures (e.g. collection of blood or tissue samples). Participation in the FOP Connection Registry or other studies in which participants complete study questionnaires are allowed.~* Treatment with another investigational drug, denosumab, imatinib or isotretinoin in the last 30 days or within 5 half-lives of the investigational drug, whichever is longer.~* Pregnant or breastfeeding women.~* Male and women of childbearing potential participants who are unwilling to practice highly effective contraception.~Note: Other protocol defined Inclusion/Exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- REGN2477 (Type: EXPERIMENTAL): None
- Placebo (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Must meet 1987 Revised Criteria for the Classification of Rheumatoid Arthritis defined as the diagnosis of the referring physician.~2. Persistent knee swelling (\>ARA grade 2) for 2 weeks, and no recent intra-articular corticosteroid injection.~3. Age 18 years and older.~4. Must be on Disease modifying anti rheumatic drugs (DMARDs) such as methotrexate, plaquenil and/or prednisone.~Exclusion Criteria:~1. Patients having received intra-articular corticosteroid joint injection within the last 2-4 weeks.~2. Patients with active systemic or joint infections.~3. Women who are pregnant (pregnancy status will be self-reported)~4. Patients under 18 years of age~5. Non-English speakers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DMARD's Responder and Non-Responder (Type: OTHER): In the first group of subjects, blood samples will be obtained from (50) RA subjects with Disease modifying anti rheumatic drugs (DMARDs) such as methotrexate, plaquenil and/or prednisone that achieve remission (DAS28\<2.6). The subjects that achieve remission (DAS28\<2.6), blood will only be taken once at the subjects routine visit. Subject's that are non-responder to DMARDS will go onto group 2.
- DMARD's plus Cimzia (Certolizumab pegol) (Type: OTHER): The second group will consist of (150) RA subjects that did not respond to DMARDs. These patients will further receive (DMARDs) such as methotrexate, plaquenil and/or prednisone as well as Cimzia®. In this Arm, blood samples will be collected onset of the study as well as 3 and 6 months after treatment with Cimzia at subject's visit through our collaboration with the aforementioned rheumatologists.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Efficacy of Infliximab (Remicade) in Pediatric Patients With Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Between the ages of 6 and 17 years~* Have had Crohn's disease diagnosed for at least 3 months prior to screening, with gastritis, duodenitis, colitis, ileitis, or ileocolitis, previously confirmed by endoscopy and biopsy~* Have active Crohn's disease despite adequate current treatment with an immunomodulator (ie, AZA, 6-MP, or MTX).~Exclusion Criteria:~* Disease complications for which surgery might be indicated~* Surgery for bowel diversion with placement of a stoma within 3 months prior to screening~* Positive stool examination for enteric pathogens including Giardia lamblia, Clostridium difficile, Shigella species, and Salmonella species.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete